Saquinavir: A Review of its Pharmacology and Clinical Potential in the Management of HIV Infection

Drugs

Volumn 52, Issue 1, 1996, Pages 93-112

  Noble, Stuart ^a   Faulds, Diana ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

[7 CHLORO 5 (1H PYRROL 2 YL) 3H BENZO[E][1,4]DIAZEPIN 2 YL]METHYLAMINE; ALPHA INTERFERON; CREATINE KINASE; EMIVIRINE; LAMIVUDINE; NEVIRAPINE; PROTEINASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ANEMIA; ANTIVIRAL ACTIVITY; ASTHENIA; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; HYPERKALEMIA; HYPOGLYCEMIA; HYPOKALEMIA; LIVER DYSFUNCTION; MOUTH ULCER; MYALGIA; NAUSEA; NEUTROPENIA; PARESTHESIA; REVIEW;

ANTI-BACTERIAL AGENTS; ANTI-HIV AGENTS; DRUG INTERACTIONS; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; SAQUINAVIR;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0029897059     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199652010-00007     Document Type: Review

References (75)

1. Levy JA. Pathogenesis of human immunodeficiency virus infection. Microbiol Rev 1993; 57 (1): 183-289
2. Pantaleo G, Graziosi C, Fauci AS. The immunopathogenesis of human immunodeficiency virus infection. N Engl J Med 1993 Feb 4; 328 (5): 327-35
3. Kohl NE, Emini EA, Schlief WA, et al. Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci USA 1988; 85: 4686-90
4. Redshaw S. Inhibitors of HIV proteinase. Expert Opin Invest Drugs 1994; 3 (3): 273-86
5. Pettit SC, Michael SF, Swanstrom R. The specificity of the HIV-1 protease. Perspect Drug Discov Des 1993; 1: 69-83
6. Vella S. Update on a proteinase inhibitor. AIDS 1994 Sep; 8 Suppl. 3: 25-9
7. Kramer RA, Schaber MD, Skalka AM, et al. HTLV-III gag protein is processed in yeast cells by the virus pol-protease. Science 1986 Mar 28; 231: 1580-4
8. Göttlinger HG, Sodroski JG, Haseltine WA. Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1989; 86: 5781-5
9. Roberts NA, Martin JA, Kinchington D, et al. Rational design of peptide-based HIV proteinase inhibitors. Science 1990 Apr 20; 248: 358-61
10. Craig JC, Grief C, Mills JS, et al. Effects of a specific inhibitor of HIV proteinase (Ro 31-8959) on virus maturation in a chronically infected promonocytic cell line (U1). Antiviral Chem Chemother 1991; 2 (3): 181-6
11. Craig JC, Duncan IB, Hockley D, et al. Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase. Antiviral Res 1991 Dec; 16: 295-305
12. Jacobsen H, Ahlborn-Laake L, Gugel R, et al. Progression of early steps of human immunodeficiency virus type 1 replication in the presence of an inhibitor of viral protease. J Virol 1992 Aug; 66: 5087-91
13. Craig JC, Duncan IB, Whittaker L, et al. Antiviral synergy between inhibitors of HIV proteinase and reverse transcriptase. Antiviral Chem Chemother 1993; 4 (3): 161-6
14. Galpin S, Roberts NA, O'Connor T, et al. Antiviral properties of the HIV-1 proteinase inhibitor Ro-8959. Antiviral Chem Chemother 1994; 5 (1): 43-5
15. Johnson VA, Merrill DP, Chou TC, et al. Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor Ro 31-8959 and zidovudine, 2′,3′-dideoxycytidine, or recombinant interferon-αA against zidovudine-sensitive or -resistant HIV-1 in vitro. J Infect Dis 1992 Nov; 166: 1143-6
16. Rusconi S, Merrill DP, Hirsch MS. Inhibition of human immunodeficiency virus type 1 replication in cytokine-stimulated monocytes/macrophages by combination therapy. J Infect Dis 1994 Dec; 170: 1361-6
17. Taylor DL, Brennan TM, Bridges CG, et al. Synergistic inhibition of human immunodeficiency virus type 1 in vitro by 6-0-butanoylcastanospermine (MDL 28 574) in combination with inhibitors of the virus-encoded reverse transcriptase and proteinase. Antiviral Chem Chemother 1995 May; 6: 143-52
18. Feorino PM, Butera ST, Folks TM, et al. Activity of the protease inhibitor Ro 31-8959 on acute, chronic and latent HIV infection [abtract no. PO-A25-0601]. IXth International Conference on AIDS; 1993 Jun 6-11; Berlin, Vol. 1, 235
19. Nitschko H, Lindhofer H, Schätzl H, et al. Long-term treatment of HIV-infected MT-4 cells in culture with HIV proteinase inhibitor Ro 31-8959 leads to complete cure of infection. Antiviral Chem Chemother 1994; 5 (4): 236-42
20. Macatonia SE, Duncan IB, Knight SC. Improved function of dendritic cells exposed in vitro to human immunodeficiency virus type 1 (HIV-1) on treatment with the proteinase inhibitor Ro 31-8959 [abstract no. PO-A25-0601]. IXth International Conference on AIDS; 1993 Jun 6-11; Berlin, Vol. 1, 235
21. Craig JC, Whittaker L, Duncan IB, et al. In vitro anti-HIV and cytotoxicological evaluation of the triple combination: AZT and ddC with HIV proteinase inhibitor saquinavir (Ro 31-8959). Antiviral Chem Chemother 1994 Nov; 5: 380-6
22. Connell EV, Hsu MC, Richman DD. Combinative interactions of a human immunodeficiency virus (HIV) Tat antagonist with HIV reverse transcriptase inhibitors and an HIV protease inhibitor. Antimicrob Agents Chemother 1994 Feb; 38: 348-52
23. Merril DP, Moonis M, Chou T-C, et al. Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro. J Infect Dis 1996; 173: 355-64
24. Brennan TM, Taylor DL, Bridges CG. The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC-442, alone and in combination with other anti-HIV compounds. Antiviral Res 1995 Mar; 26: 173-87
25. Craig JC, Whittaker L, Duncan IB, et al. In vitro resistance to an inhibitor of HIV proteinase (Ro 31-8959) relative to inhibitors of reverse transcriptase (AZT and TIBO). Antiviral Chem Chemother 1993; 4 (6): 335-9
26. Dianzani F, Antonelli G, Turriziani O, et al. In vitro selection of human immunodeficiency virus type 1 resistant to Ro 31-8959 proteinase inhibitor. Antiviral Chem Chemother 1993; 4 (6): 329-33
27. Jacobsen H, Craig CJ, Duncan IB, et al. Molecular characterization of HIV-variants with reduced sensitivity to Ro 31-8959, a viral proteinase inhibitor [abstract]. AIDS Res Hum Retroviruses 1994 Aug; 10 Suppl. 1: S24
28. Turriziani O, Antonelli G, Jacobsen H, et al. Identification of an amino acid substitution involved in the reduction of sensitivity of HIV-1 to an inhibitor of viral proteinase. Acta Virol 1994; 38: 297-8
29. Tisdale M, Myers RE, Maschera B, et al. Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob Agents Chemother 1995 Aug; 39: 1704-10
30. Eberle J, Bechowsky B, Rose D, et al. Resistance of HIV type 1 to proteinase inhibitor Ro 31-8959. AIDS Res Hum Retroviruses 1995 Jun; 11: 671-6
31. Jacobsen H, Yasargil K, Winslow DL, et al. Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology 1995; 206 (1): 527-34
32. Roberts NA. Drug-resistance patterns of saquinavir and other HIV proteinase inhibitors. AIDS 1995; 9 Suppl. 2: S27-32
33. Hoffmann-La Roche (Basel). Resistance and cross resistance to inhibitors of HIV proteinase - studies with saquinavir (Invirase™). 1996. (Data on file)
34. Partaledis JA, Yamaguchi K, Tisdale M, et al. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J Virol 1995; 69 (9): 5228-35
35. Hoffmann-La Roche Inc. Invirase™(saquinavir mesylate) capsules prescribing information. Nutley, New Jersey, USA, 1996
36. Schapiro JM, Winters MA, Kozal MJ, et al. Saquinavir monotherapy trial: prolonged suppression of viral load and resistance mutations with higher dosage [abstract no. LB-5]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17-20; San Francisco, 8
37. Jacobsen H, Haenggi M, Ott M, et al. Reduced sensitivity to saquinavir: an update on genotyping from phase I/II trials. Antiviral Res 1996; 29: 95-7
38. Vella S, Galluzzo C, Giannini G, et al. Saquinavir/zidovudine combination in patients with advanced HIV infection and no prior antiretroviral therapy: CD4+ lymphocyte/plasma RNA changes, and emergence of HIV strains with reduced phenotypic sensitivity. Antiviral Res 1996; 29: 91-3
39. Condra JH, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995 Apr 6; 374: 569-71
40. Williams PEO, Sampson AP, Green CP, et al. Disposition and bioavailability of the HIV-proteinase inhibitor. Ro 31-8959, after single doses in healthy volunteers. Br J Clin Pharmacol 1992 Aug; 34: 155P-6P
41. Hoffmann-La Roche, Ro 31-8959 Saquinavir Invirase™. Investigational Drug Brochure. W-144'962. 1996. (Data on file)
42. Shaw TM, Muirhead GJ, Parish N, et al. Tolerability and pharmacokinetics of single oral doses of Ro 31-8959, an HIV proteinase inhibitor. Br J Clin Pharmacol 1994 Aug; 34: 166P-7P
43. Muirhead GJ, Shaw T, Williams PEO, et al. Pharmacokinetics of the HIV-proteinase inhibitor, Ro 318959, after single and multiple oral doses in healthy volunteers. Br J Clin Pharmacol 1992 Aug; 34: 170P-1P
44. Stewart F, Williams PEO, Delfraissy JF, et al. Modelling of a concentration-response relationship during monotherapy with the proteinase inhibitor Ro 31-8959 in HIV infected patients [abstract no. P1-90]. 95th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 1994 Mar 30-Apr 1; New Orleans, 145
45. Farrar G, Mitchell AM, Hooper H, et al. Prediction of potential drug interactions of saquinavir (Ro 31-8959) from in vitro data. Br J Clin Pharmacol 1994 Aug; 38: 162P
46. Norbeck D, Kumar G, Marsh K, et al. Ritonavir and saquinavir: potential for two-dimensional synergy between HIV protease inhibitors [abstract no. LB-7]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17-20; San Francisco, 9
47. Kitchen VS, Skinner C, Ariyoshi K, et al. Safety and activity of saquinavir in HIV infection. Lancet 1995 Apr 15; 345: 952-5
48. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996; 334: 1011-7
49. Lagakos SW, Hoth DF. Surrogate markers in AIDS: Where are we? Where are we going? Ann Intern Med 1992; 116 (7): 599-601
50. Yarchoan R, Venzon DJ, Pluda JM, et al. CD4 count and the risk for death in patients infected with HIV receiving antiretroviral therapy. Ann Intern Med 1991; 115 (3): 184-9
51. De Gruttola V, Wulfsohn M, Fischl MA, et al. Modeling the relationship between survival and CD4 lymphocytes in patients with AIDS and AIDS-related complex. J Acquir Immune Defic Syndr 1993; 6: 359-65
52. + lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine. Ann Intern Med 1993; 118: 674-80
53. Hoffmann-La Roche (Nutley). 1996. (Data on file)
54. Roche Invirase clears FDA in 97 days as first approved protease inhibitor: new formulation in study: international confirmatory trial size, power increased. FDC Rep Pink Sheet 1995; Dec 11: 3-4
55. Roche Invirase combined with nucleosides shows greater surrogate marker activity in AZT-naive patients: confirmatory trials may need more patients. FDC Rep Pink Sheet 1995; Nov 13: 14-6
56. Evaluation and management of early HIV infection: guideline overview. J Natl Med Assoc 1994; 86 (3): 173-6
57. Whittington R, Brogden RN. Zalcitabine: a review of its pharmacology and clinical potential in Acquired Immunodeficiency Syndrome (AIDS). Drugs 1992 Apr; 44 (4): 656-83
58. Faulds D, Brogden RN. Didanosine: a review of its antiviral activity, pharmacokinetic properties and therapeutic potential in Human Immunodeficiency Virus infection. Drugs 1992 Jan; 44 (1): 94-116
59. Abrams DI. Treatment options in zidovudine intolerance or failure. AIDS 1994; 8 Suppl. 3: S3-7
60. Cooper DA. Early antiretroviral therapy. AIDS 1994; 8 Suppl. 3: S9-S14
61. Hirsch MS, Yeni P. A bend in the road - implications of ACTG 175 and Delta trials [editorial]. Antiviral Ther 1996; 1 (1): 6-8
62. Stephenson J. Other AIDS drug regimens beat AZT alone, reduce clinical progression and mortality. JAMA 1995; 274 (15): 1183-4
63. Videx & Hivid cleared for wider use. Scrip 1996; No. 2109 Mar 8: 19
64. Bristol Videx initial HIV therapy recommended based on 50% death risk reduction over AZT; DDI/AZT combination should be in labeling, committee says. FDC Rep Pink Sheet 1996; Mar 4: 9-10
65. Pinching AJ. Managing HIV disease after Delta: questions remain about how to manage patients already on nucleoside monotherapy. BMJ 1996 Mar 2; 312: 521-2
66. Abbot Norvir for HIV reduces death risk 40%, reduces disease progression risk 55% in advanced HIV; FDA approves ritonavir March 1 in record 72 days. FDC Rep Pink Sheet 1996; Mar 4: 7-8
67. Merck Crixivan should not be limited to specific subpopulations, FDA committee says; combo therapy may have advantage in viral load. FDC Rep Pink Sheet 1996; Mar 11: 15-6
68. Abbot's ritonavir survival advantage. Scrip 1996; No. 2101 Feb 9: 21
69. Protease inhihilor cocktails set new standards for HIV therapy. Scrip 1996; No. 2100 Feb 6: 17
70. Moyle G, Gazzard B. Current knowledge and future prospects for the use of HIV protease inhihitors. Drugs 1996 May; 51 (5): 701-12
71. FDA recommends new AIDS drug. Press release, The Associated Press, 29 Feb 1996.
72. New drugs for HIV infection. Med Lett Drugs Ther 1996; 38 (972): 35-7
73. Hoffmann-La Roche (Basel). Saquinavir: ongoing trials. 1996. (Data on file)
74. Soo W, Nauss-Karol C, Elkins M, et al. Inter-company collaboration combination trials. J Acquir Immune Defic Syndr 1995; 10 Suppl. 2: S92-96
75. Combination AIDS trial starts. Scrip 1996; No. 2126 May 7: 18